Global Allogeneic Stem Cell Transplantation Market Size, Share, and COVID-19 Impact Analysis, By Source (Bone Marrow, Peripheral Blood, Umbilical Cord Blood, Adipose Tissue, Dental Pulp, and Others), By Type of Stem Cells (Hematopoietic Stem Cells, Mesenchymal Stem Cells, and Others), By End User (Hospitals, Research Institutes, Specialty Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Allogeneic Stem Cell Transplantation Market Insights Forecasts to 2035

• The Global Allogeneic Stem Cell Transplantation Market Size Was Estimated at USD 4.20 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.70% from 2025 to 2035
• The Worldwide Allogeneic Stem Cell Transplantation Market Size is Expected to Reach USD 9.50 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The Global Allogeneic Stem Cell Transplantation Market Size was worth around USD 4.20 Billion in 2024 and is predicted to Grow to around USD 9.50 Billion by 2035 with a compound annual growth rate (CAGR) of 7.70% from 2025 to 2035. The growing prevalence of chronic diseases, including cancer, autoimmune diseases, and blood disorders, is responsible for driving the allogeneic stem cell transplantation market globally.

Market Overview

The allogeneic stem cell transplantation market is the market that focuses on the medical procedure where patients receive healthy stem cells from a donor to replace their own damaged or diseased stem cells. Allogeneic stem cell transplantation (SCT) refers to the use of stem cells from someone other than the patient. Allogeneic SCT is often used to treat blood cancers like leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Emergence of complex technologies such as gene editing and cell therapy is improving and optimizing outcomes of stem cell transplantation, minimizing potential adverse effects, and broadening the list of potential stem cell donors. The growing emphasis on personalized medicine and tailored treatment approaches for enhancing the efficacy and safety of transplants is offering growth opportunity in allogeneic stem cell transplantation.

Report Coverage

This research report categorizes the allogeneic stem cell transplantation market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the allogeneic stem cell transplantation market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the allogeneic stem cell transplantation market.

Driving Factors

The increasing prevalence of autoimmune chronic conditions, including hematologic malignancies and bone marrow failure syndromes, is anticipated to drive the market demand. The use of innovative targeted and immunomodulatory medications in combination with allo-SCT for enhancing therapeutic efficacy is promoting the market. There are ongoing research and development activities for managing complications like graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Additionally, the growing emphasis on regenerative medicine research is contributing to propel the market growth of allogeneic stem cell transplantation.   

Restraining Factors

The limited donor availability and lack of awareness regarding transplantation, particularly in emerging economies, are hampering the market growth. Further, the increased cost of cell therapies and stringent regulatory frameworks are negatively impacting the market.

Market Segmentation

The allogeneic stem cell transplantation market share is classified into source, type of stem cells, and end user.

• The bone marrow segment held the dominant market share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the source, the allogeneic stem cell transplantation market is divided into bone marrow, peripheral blood, umbilical cord blood, adipose tissue, dental pulp, and others. Among these, the bone marrow segment held the dominant market share in 2024 and is projected to grow at a substantial CAGR during the forecast period. Bone marrow transplantation aids in eradicating leukemia stem cells after intensive chemotherapy or radiation. The increased preference for bone marrow transplants due to their high success rate and ability to regenerate the immune system and restore normal blood cell production is supporting the market.

• The hematopoietic stem cells segment dominated the allogeneic stem cell transplantation market in 2024 and is expected to grow at a significant CAGR during the forecast period.

Based on the type of stem cells, the allogeneic stem cell transplantation market is divided into hematopoietic stem cells, mesenchymal stem cells, and others. Among these, the hematopoietic stem cells segment dominated the allogeneic stem cell transplantation market in 2024 and is expected to grow at a significant CAGR during the forecast period. Hematopoietic stem cells are mainly used for treating blood-related conditions like leukemia and lymphoma. The ongoing research on developing stem-cell-based medicines is anticipated to drive significant market growth.

• The hospitals segment dominated the allogeneic stem cell transplantation market in 2024 and is anticipated to grow at a rapid CAGR during the forecast period.

Based on the end user, the allogeneic stem cell transplantation market is divided into hospitals, research institutes, specialty clinics, and others. Among these, the hospitals segment dominated the allogeneic stem cell transplantation market in 2024 and is anticipated to grow at a rapid CAGR during the forecast period. The availability of well-equipped units in hospitals, including bone marrow transplantation units for stem cell transplantation, is responsible for driving the market demand in the hospitals segment.

Regional Segment Analysis of the Allogeneic Stem Cell Transplantation Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the allogeneic stem cell transplantation market over the predicted timeframe.

North America is anticipated to hold the largest share of the allogeneic stem cell transplantation market over the predicted timeframe. The presence of leading medical centers and universities, and centers of biotech developments in countries like the USA and Canada, is propelling the allogeneic stem cell transplantation market in the region. Advanced healthcare infrastructure and the adoption of stem cell therapies are propelling the market growth of allogeneic stem cell transplantation.

Asia Pacific is expected to grow at a rapid CAGR in the allogeneic stem cell transplantation market during the forecast period. An increasing number of stem cell-based therapies, with a growing biotechnology sector in the region, is driving the market. With the increasing population in the region, government support for research and development activities for stem cell transplantation therapy is promoting the market.

Europe is anticipated to hold a significant share of the allogeneic stem cell transplantation market during the predicted timeframe. An increasing prevalence of cancers and blood disorders in the region is anticipated to propel the allogeneic stem cell transplantation market. The heightened rate of stem cell transplantation, regulatory support, and significant investment in stem cell research are driving the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the allogeneic stem cell transplantation market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Celgene Corporation
• Mesoblast Ltd.
• Pluristem Therapeutics Inc.
• MEDIPOST Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• Cellular Biomedicine Group, Inc.
• Biosolution Co., Ltd.
• StemCell Technologies Inc.
• Caladrius Biosciences, Inc.
• TiGenix N.V.
• ViaCord
• Vericel Corporation
• Regen Biopharma Inc.
• Gamida Cell Ltd.
• Histogenics Corporation
• BrainStorm Cell Therapeutics Inc.
• Lineage Cell Therapeutics, Inc.
• Bluebird Bio
• Sanofi
• Talaris Therapeutics
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In February 2025, Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced that the company had initiated the DOSED clinical study.

• In January 2025, Sana Biotechnology, Inc., announced the initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogenic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the allogeneic stem cell transplantation market based on the below-mentioned segments: 

Global Allogeneic Stem Cell Transplantation Market, By Source

• Bone Marrow
• Peripheral Blood
• Umbilical Cord Blood
• Adipose Tissue
• Dental Pulp
• Others

Global Allogeneic Stem Cell Transplantation Market, By Type of Stem Cells

• Hematopoietic Stem Cells
• Mesenchymal Stem Cells
• Others

Global Allogeneic Stem Cell Transplantation Market, By End User

• Hospitals
• Research Institutes
• Specialty Clinics
• Others

Global Allogeneic Stem Cell Transplantation Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa